What Are the Treatment Options for Stage III NSCLC?

Learn why stage III NSCLC requires an individualized approach to treatment.

Cancer cells on a glass slide for examination. Biopsy can provide important information about cancer.

Sometimes referred to as “locally advanced” non-small-cell lung cancer, stage III NSCLC generally refers to cases where the cancer may have spread to other structures throughout the chest, but has not spread to the other lung or metastasized to other sites in the body. Stage III NSCLC tumors are sometimes described as “heterogeneous”—which means diverse, varied, or disparate. What this description means is that there can be a great deal of variance among the cancer cells in stage III NSCLC, and not all cases of stage III NSCLC are vulnerable to the same treatments.

As a result, treatment for stage III NSCLC is highly individualized, meaning that a treatment plan is at least somewhat different for every person diagnosed with this type of cancer. Here, we look at the reasons for this approach and the various treatments that may be used in treating stage III NSCLC.


When deciding on a treatment for stage III NSCLC, a healthcare team will gather as much information as possible about the cancer and about the patient. Some of this information may have been gathered in the diagnosis and staging process, such as the size and locations of the tumors, if the cancer has spread to lymph nodes, and if the cancer is impacting other tissues and organs around the lungs. This information will be considered when deciding on a treatment plan.

Biomarker testing

Biomarkers are specific characteristics about the molecular biology of a cancer. Some cancer treatments—targeted therapies and immunotherapies—are able to target biomarkers. Biomarker testing can help determine if these therapies may be effective at treating a specific case of NSCLC.

The patient being treated

Information about the person who is undergoing treatment for NSCLC is also very important when deciding on an approach to treatment. Some of the factors that a healthcare team will consider include:

  • Medical history. Including any previous cancer treatments and other health conditions, such as chronic obstructive pulmonary disease (COPD) or cardiovascular disease.
  • Age and overall health. Cancer treatments cause side effects and take a toll on the body, and the impact cancer treatment will have on a person’s life and health will be considered.
  • Patient preferences and needs. While patients should follow the guidance of their healthcare team, they should have a clear understanding of their treatment options, what side effects to expect, and the pros and cons of different treatments. Anyone undergoing treatment should discuss their concerns and questions with their healthcare team.

Treatment options

While a person’s treatment plan for NSCLC will depend on the factors described above, these are the commonly used treatments for stage III NSCLC:

  • Chemotherapy and radiation therapy. Chemotherapy used in combination with radiation therapy (called “chemoradiotherapy” or “chemoradiation”) is a staple of treatment for stage III NSCLC. Chemotherapy or “chemo” drugs contain powerful chemicals that destroy cancer cells or stop cancer cells from spreading. Radiation therapy typically uses X-rays to shrink or destroy specific tumors. These treatments may be used concurrently or sequentially.
  • Targeted therapies. Biomarker testing can identify certain proteins that aid cancer growth in some cases. Targeted therapies work by blocking or inhibiting these proteins, interfering with the growth and spread of cancer cells.
  • Immunotherapy. Biomarker testing can also determine if cancer is PD-L1 positive. PD-L1 is a protein found on the surface of cancer cells in some cases. This protein signals the immune system to ignore these cancer cells. Immunotherapy drugs disable this protein or reduce the amount of this protein in the body, which allows the immune system to attack the cancer cells. Immunotherapies are somewhat unique in that they do not attack cancer cells directly, but help the immune system attack cancer.
  • Surgery. Surgery may be used along with other therapies to remove specific tumors or lymph nodes, or to remove part or all of the diseased lung.

Remember, not every treatment is appropriate for every patient. The best thing a person with stage III NSCLC can do is work with a team of healthcare providers who can guide them through the best treatment options.

Article sources open article sources

UpToDate. "Patient education: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)."
Lungevity. "Lung Cancer Staging."
UpToDate. "Patient education: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)."
UpToDate. "Management of stage III non-small cell lung cancer."
Eva Kiesler. "What Is Tumor Heterogeneity?" Memorial Sloan Kettering Cancer Center, 2014.
Gregory L. Riely. "What, When, and How of Biomarker Testing in Non–Small Cell Lung Cancer." Official Journal of the National Comprehensive Cancer Network, 2017. Vol. 15, No. 5s.
Xiaojuan Ai, Xialing Guo, Jun Wang, Andreea L. Stancu, Patrick M.N. Joslin, Dianzheng Zhang, and Shudong Zhu. "Targeted therapies for advanced non-small cell lung cancer." Oncotarget, 2019. Vol. 9, No. 101.
Mayo Clinic. "Lung Cancer."
Keith Sigel and Juan P. Wisnivesky. "Comorbidity Profiles of Patients with Lung Cancer: A New Approach to Risk Stratification?" Annals of the American Thoracic Society, 2017. Vol. 14, No. 10.
K. M. Islam, T. Anggondowati, et al. "Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer." BMC Cancer, 2019. Vol. 19, No. 1.
Lungevity. "Patient Preferences and Needs."
NCI Dictionary of Cancer Terms. "Chemoradiation."
American Cancer Society. "Chemotherapy for Non-Small Cell Lung Cancer."
American Cancer Society. "Radiation Therapy for Non-Small Cell Lung Cancer."
Medical News Today. "What to know about stage 3 lung cancer."

Featured Content


Biomarker Testing for Non-Small Cell Lung Cancer

Get the essential facts about this important tool for the diagnosis and treatment of non-small cell lung cancer.

9 Numbers to Know for Lung Cancer Awareness Month

Statistics that highlight the impact of lung cancer in the United States.

Tips When Researching Lung Cancer

Strategies for sorting through information from scientific studies, patient education materials, and clinical trials.

How Diverse Communities Are Impacted by NSCLC

Several disparities, including overall healthcare access, can impact the prevalence of NSCLC in diverse communities.

How to Avoid “Caregiver Burnout"

Caregiver burnout is a very real form of physical, emotional and mental exhaustion.